
CVS$81.33▲ 1.7%CVS's next drugstore chief only sold on the market since 2022. Then he bought $2 million
Prem Shah, named by CVS Health on Nov. 4 to run its drugstores as a separate company, bought about $2 million of CVS stock on Nov. 6, his filing shows. That company has no shares yet.
KeyVex News··5 min readFact-checked against 9 public records
KeyVex News··5 min readFact-checked against 9 public records
CVS$81.33▲ 1.7%Close, Nov. 5. Prices from Tiingo.The short versionTap to readTap to close
- Since Prem Shah began filing as a CVS officer in January 2022, every trade he made in CVS stock on the open market was a sale, about $5.1 million in all.
- On Nov. 4, CVS named him to run its drugstores as a separate company after a split. On Nov. 6 he bought 23,855 CVS shares, about $2 million.
- That drugstore company has no stock of its own until the split. CVS shareholders will own shares in both companies, so a CVS share today stands for both businesses.
- His filing does not mark the purchase as made under a pre-set trading plan, and it does not say why he bought.
- Next on paper: an SEC registration statement, which the release lists as a condition of the split. None had been filed publicly under CVS Health as of Nov. 6.
The purchase: Prem Shah, the CVS Health group president who is to run CVS Pharmacy, the drugstore company CVS plans to separate, bought 23,855 CVS shares on Nov. 6 at $83.895 each, his filing shows.Form 4Release That is about $2.0 million. After it, he held about 88,500 CVS shares directly, his filing shows, not counting restricted shares and options his earlier filings report.Form 4
The record: It is the first open-market purchase in his filings: shares he bought at the market price, not shares granted to him or received through options.Form 4EDGAR His filings begin with the report he filed as a new CVS officer in January 2022.Form 3 Until now, every open-market trade in them was a sale: 56,397 shares for about $5.1 million, in 2022 and 2024.Form 4Form 4Form 4Form 4
Why it matters: The company he is to run does not trade yet. CVS shareholders are to receive shares in both companies when the split is done.Release Until then, the only way to own CVS Pharmacy is to own CVS, so his purchase is a stake in all of it, the Aetna insurer and the Caremark drug-benefit business included.Release
CVS Health's stock since Prem Shah began filing as an officerDaily close, Jan. 10, 2022 to Nov. 5, 2026 ▼ 22.6%Show chartHide chart
The price
CVS closed at $91.41 on Nov. 3, the last day before the plan was announced.KeyVex On Nov. 4 it closed at $79.96, down 12.5%.KeyVex Only two days in the last 10 years were worse for the stock: May 1, 2024, and Jan. 27, 2026.KeyVex Leerink analyst Michael Cherny put part of the premarket drop down to uncertainty about the deal and to swings in health stocks after the midterm elections, Reuters reported.Reuters Shah's $83.895 was above the Nov. 5 close of $81.33 and below the Nov. 3 close.Form 4KeyVex
What he did before
In March and April 2022, Shah sold 26,924 shares at $104.70 to $106.65.Form 4Form 4Form 4 Most came from stock options he exercised the same day.Form 4Form 4Form 4 His filings say the March 30 and April 8 sales were made under a Rule 10b5-1 plan, which sets trades in advance.Form 4Form 4
On Feb. 16, 2024, he sold 29,473 shares at an average $76.95, about $2.3 million.Form 4 That filing does not mark the sale as made under such a plan, and neither does the Nov. 6 filing for his purchase.Form 4Form 4
View the data
| Trade date | Bought (+) or sold (-), $ millions | Note |
|---|---|---|
| Mar. 17, 2022 | -$0.49M | Sold 4,624 shares at $106.65: $493,150 |
| Mar. 30, 2022 | -$0.56M | Sold 5,346 shares at $104.70 after an option exercise: $559,726 |
| Apr. 8, 2022 | -$1.78M | Sold 16,954 shares at $105.00: $1,780,170 |
| Feb. 16, 2024 | -$2.27M | Sold 29,473 shares at an average $76.95: $2,267,947 |
| Nov. 6, 2026 | $2.00M | Bought 23,855 shares at $83.895: $2,001,315 |
Shares times the price each filing gives, rounded to $0.01 million. Source: Prem Shah's Form 4s for CVS Health.Data
The company he is to run
CVS Pharmacy is to take about 9,000 drugstores, the mail pharmacy, the MinuteClinic walk-in clinics and a technology business called Health100.Release CVS's drugstore segment, which does not line up exactly with the new company, had $35.5 billion of revenue in the third quarter, down 2.0%.Q3 release Its adjusted operating income, a profit measure CVS uses, rose 10.6%.Q3 release
CVS put the revenue drop mainly on price cuts on some drugs tied to regulation, new generic drugs and pressure on what pharmacies are paid.Q3 release KeyVex reported on Nov. 4 on the plan and on how CVS stock has done since it bought Aetna in 2018.
How others read it
CVS Pharmacy will have to stand alone against challenges that have driven some pharmacy operators to go private or into bankruptcy, Healthcare Dive reported.Healthcare Dive Rival Walgreens was acquired by the private equity firm Sycamore Partners in 2025, Reuters reported.Reuters CVS drugstores also face competition from Amazon and a shift to prescription delivery, according to the same report.Reuters
Cherny wrote that the breakup "feels like a complete shock," Healthcare Dive reported.Healthcare Dive He also wrote that "perhaps the outlook for a standalone retail pharmacy" is "stronger now than before," Healthcare Dive reported.Healthcare Dive Morningstar analyst Julie Utterback said improving results "probably helped with the timing of the move," according to Reuters.Reuters
What comes next
The split is not final. It is subject to conditions including the board's final approval, an effective SEC registration statement and confirmation that it is tax-free for CVS and its shareholders, the release says.8-KRelease CVS expects to complete the split in the first half of 2028.Release No such registration statement had been filed publicly under CVS Health as of Nov. 6.EDGAR
What to watch
The paper trail
The filings cited here, with the time EDGAR accepted them (Eastern), Jan. 10, 2022 through Nov. 6, 2026.
| Filed (ET) | Form | Filer | What it shows |
|---|---|---|---|
| Nov. 6, 2026, 4:41 p.m. | 4 | Prem S. Shah | Bought 23,855 CVS shares at $83.895 on Nov. 6; 88,516.1575 shares held directly after. |
| Nov. 4, 2026, 6:34 a.m. | 8-K | CVS Health | Item 7.01: the plan to separate into two public companies, with Shah to lead CVS Pharmacy (Exhibit 99.1). |
| Nov. 4, 2026, 6:31 a.m. | EX-99.1 | CVS Health | Third-quarter 2026 results, including the Pharmacy & Consumer Wellness segment. |
| Feb. 16, 2024, 6:46 p.m. | 4 | Prem S. Shah | Sold 29,473 shares at an average $76.95 on Feb. 16, 2024. |
| April 12, 2022, 4:51 p.m. | 4 | Prem S. Shah | Option exercises and sales of 16,954 shares at $105.00 on April 8, 2022, under a Rule 10b5-1 plan. |
| March 31, 2022, 4:49 p.m. | 4 | Prem S. Shah | Option exercise and sale of 5,346 shares at $104.70 on March 30, 2022, under a Rule 10b5-1 plan. |
| March 18, 2022, 4:55 p.m. | 4 | Prem S. Shah | Sales of 4,624 shares at $106.65 on March 17, 2022. |
| Jan. 10, 2022, 5:13 p.m. | 3 | Prem S. Shah | Initial report of his CVS holdings as an executive officer. |
Related coverage
Sources
14 sources, 9 of them public records
Public records
- Prem S. Shah, Form 4: statement of changes in beneficial ownership, CVS Health (purchase of Nov. 6, 2026)SEC EDGAR · Nov. 6, 2026
- "CVS Health Announces Intent to Create Two Distinct Leaders in Healthcare" (Form 8-K, Exhibit 99.1)SEC EDGAR · Nov. 4, 2026
- CVS Health Corporation, Form 8-K, Item 7.01: Regulation FD DisclosureSEC EDGAR · Nov. 4, 2026
- CVS Health third-quarter 2026 results (Form 8-K, Exhibit 99.1)SEC EDGAR · Nov. 4, 2026
- Prem S. Shah, Form 4, CVS Health (sale of Feb. 16, 2024)SEC EDGAR · Feb. 16, 2024
- Prem S. Shah, Form 4, CVS Health (exercises and sales of April 8, 2022)SEC EDGAR · April 12, 2022
- Prem S. Shah, Form 4, CVS Health (exercise and sale of March 30, 2022)SEC EDGAR · March 31, 2022
- Prem S. Shah, Form 4, CVS Health (sales of March 17, 2022)SEC EDGAR · March 18, 2022
- Prem S. Shah, Form 3: initial statement of beneficial ownership, CVS HealthSEC EDGAR · Jan. 10, 2022
Rules and references
- Prem S. Shah (CIK 1900910), filings listSEC EDGAR · checked Nov. 6, 2026
- CVS Health Corporation filings, SEC EDGAR company search (Form 10 registrations)SEC EDGAR · checked Nov. 6, 2026
Reporting
- "CVS to split into two companies in stunning strategic about-face"Healthcare Dive · Nov. 4, 2026
- "CVS Health to split in two, separating pharmacy business from insurance" (Reuters)NBC News · Nov. 4, 2026
Data
- Daily closing prices for CVS (Tiingo)KeyVex · through Nov. 5, 2026
How we got these numbers
- Shah's trades are from his own Form 4s, read from the filings, not from a dataset summary. The Nov. 6 purchase: 23,855 shares at $83.895 = $2,001,315; unrestricted common shares held directly after it, 88,516.1575, rounded in the text to about 88,500. His April 2, 2026 Form 4 also reported 62,852 restricted shares held directly, and earlier filings report stock options and deferred stock units; the text does not add them in. His filings list is from SEC EDGAR (CIK 1900910): a Form 3 on Jan. 10, 2022, then Form 4s; the only open-market purchase (code P) among them is Nov. 6, 2026. They also report grants, option exercises and shares withheld for taxes, which are not open-market trades.
- Open-market sales: March 17, 2022, 4,624 shares at $106.65 ($493,149.60); March 30, 2022, 5,346 at $104.70 ($559,726.20); April 8, 2022, 16,954 at $105.00 ($1,780,170.00); Feb. 16, 2024, 29,473 at a weighted average $76.95 ($2,267,947.35). Total 56,397 shares and $5,100,993.15, about $5.1 million. The March 30 and April 8, 2022 filings carry a footnote that the sales were made under a Rule 10b5-1 plan; the March 17, 2022 filing carries none; the Feb. 16, 2024 and Nov. 6, 2026 filings leave the 10b5-1 box unchecked.
- Prices are closes as traded. Nov. 4, 2026: $91.41 to $79.96, -12.5%. Across KeyVex's CVS closes from Nov. 7, 2016 to Nov. 5, 2026, the only larger one-day falls were May 1, 2024 (-16.8%) and Jan. 27, 2026 (-14.2%). Segment figures are from CVS's Nov. 4 results release: Pharmacy & Consumer Wellness revenue of $35,498 million, against $36,214 million a year earlier, and adjusted operating income of $1,635 million, against $1,478 million.
- The S&P 500 line in the stock chart follows SPY, as traded, rebased. The Filings switch shows the filing markers from KeyVex's CVS stock page, a selection of congressional trades, insider sales, Form 144 notices, 8-Ks and lobbying filings: not every filing, and not only those tied to this story. The header image was generated for KeyVex by an image model. It is an illustration, not a photograph of a real store. This is a reading of public filings and news reports, not investment advice.





